Status:
COMPLETED
Bone Marrow Suppression and Recovery During Radionuclide Treatment
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Castration-resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant prostate cancer and bone metastases. More than 20 % of patients treated at Rigshospitalet develop bone marro...
Detailed Description
Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant prostate cancer and bone metastases. Therapy is administered intravenously every 4 weeks for up to 6 cycles....
Eligibility Criteria
Inclusion
- Metastatic castration resistant prostate cancer
- Planned to initiate Radium therapy
- Age \> 18 years
- Able to understand study protocol and give informed consent
Exclusion
- None
Key Trial Info
Start Date :
June 20 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT03247010
Start Date
June 20 2017
End Date
October 1 2020
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100